Loading...
XPAR
BIM
Market cap14bUSD
Dec 04, Last price  
104.20EUR
1D
-1.98%
1Q
-11.92%
Jan 2017
120.30%
IPO
942.00%
Name

Biomerieux SA

Chart & Performance

D1W1MN
XPAR:BIM chart
P/E
28.46
P/S
3.09
EPS
3.66
Div Yield, %
0.82%
Shrs. gr., 5y
—
Rev. gr., 5y
8.27%
Revenues
3.98b
+8.31%
993,600,0001,036,900,0001,062,800,0001,110,500,0001,223,400,0001,357,000,0001,427,200,0001,569,800,0001,587,900,0001,698,400,0001,964,600,0002,103,199,9992,288,200,0002,421,300,0002,674,800,0003,118,200,0003,376,200,0003,589,100,0003,674,700,0003,979,900,000
Net income
432m
+20.86%
90,100,000105,300,00098,100,000130,000,000148,200,000160,000,000160,500,000134,400,000164,300,000134,900,000110,500,000179,100,000238,100,000256,600,000272,800,000404,400,000601,100,000452,400,000357,600,000432,200,000
CFO
667m
+49.82%
164,500,000124,600,000188,700,000197,900,000188,600,000199,000,000216,600,000258,500,000240,500,000298,300,000310,000,000335,600,000341,300,000399,800,000407,900,000582,800,000824,700,000475,100,000445,400,000667,300,000
Dividend
Jun 09, 20250.9 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
URL
https://www.biomerieux.fr/
IPO date
Jun 07, 2004
Employees
12,557
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT